SK6702000A3 - Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use - Google Patents

Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use Download PDF

Info

Publication number
SK6702000A3
SK6702000A3 SK670-2000A SK6702000A SK6702000A3 SK 6702000 A3 SK6702000 A3 SK 6702000A3 SK 6702000 A SK6702000 A SK 6702000A SK 6702000 A3 SK6702000 A3 SK 6702000A3
Authority
SK
Slovakia
Prior art keywords
alkyl
adenosine
methyl
group
alk
Prior art date
Application number
SK670-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Colin David Eldred
Andrew Michael Kenneth Pennell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SK6702000A3 publication Critical patent/SK6702000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK670-2000A 1997-11-08 1998-11-06 Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use SK6702000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723590.7A GB9723590D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007023 WO1999024451A2 (fr) 1997-11-08 1998-11-06 Composes chimiques

Publications (1)

Publication Number Publication Date
SK6702000A3 true SK6702000A3 (en) 2001-01-18

Family

ID=10821761

Family Applications (1)

Application Number Title Priority Date Filing Date
SK670-2000A SK6702000A3 (en) 1997-11-08 1998-11-06 Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use

Country Status (27)

Country Link
US (2) US6544960B1 (fr)
EP (1) EP1030856B1 (fr)
JP (1) JP2001522859A (fr)
KR (1) KR20010031878A (fr)
CN (1) CN1217952C (fr)
AP (1) AP2000001804A0 (fr)
AT (1) ATE273989T1 (fr)
AU (1) AU763414B2 (fr)
BR (1) BR9813989A (fr)
CA (1) CA2309202C (fr)
DE (1) DE69825779T2 (fr)
EA (1) EA003087B1 (fr)
EE (1) EE04499B1 (fr)
ES (1) ES2222619T3 (fr)
GB (1) GB9723590D0 (fr)
HR (1) HRP20000277A2 (fr)
HU (1) HUP0004102A3 (fr)
ID (1) ID24758A (fr)
IL (2) IL135966A0 (fr)
IS (1) IS5479A (fr)
NO (1) NO20002359L (fr)
NZ (1) NZ504336A (fr)
PL (1) PL340873A1 (fr)
SK (1) SK6702000A3 (fr)
TR (1) TR200001937T2 (fr)
WO (1) WO1999024451A2 (fr)
YU (1) YU26800A (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
WO2001040799A2 (fr) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Procede d'identification d'agonistes partiels des recepteurs de l'adenosine a1 et utilisation de ces agonistes pour le traitement des arythmies
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
GB9930085D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
EP1258247A1 (fr) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Analogues d'adénosine pour le traitement de le diabete et de la resistance à l' insuline
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
GB0221694D0 (en) * 2002-09-18 2002-10-30 Glaxo Group Ltd Compounds
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
ES2574918T3 (es) * 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
EP1648952B1 (fr) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Supplements alimentaires et compositions therapeutiques comportant des derives (r)-3-hydroxybutyrates
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
DK2240017T3 (da) 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
CN101602786B (zh) * 2008-06-10 2014-04-30 中国医学科学院药物研究所 N6-取代腺苷衍生物、其制法以及药物组合物与用途
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
CN101857622B (zh) * 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
CN104382924B (zh) * 2009-12-10 2017-12-22 中国医学科学院药物研究所 N6‑取代腺苷衍生物和n6‑取代腺嘌呤衍生物及其用途
CN102812033B (zh) * 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2914251B1 (fr) 2012-11-05 2019-08-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Corps cétoniques destinés à protéger les tissus des lésions par rayonnement ionisant
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
CA2903114A1 (fr) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Formulations ophtalmiques
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
CA2954862A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polytherapie
CA3102279A1 (fr) 2018-06-01 2019-12-05 Cornell University Polytherapie pour maladie ou trouble associe a pi3k
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868160A (en) * 1985-11-06 1989-09-19 Warner-Lambert Company Method of treating psychosis using N6 -substituted -5'-oxidized adenosine analogs
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
AU654507B2 (en) * 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
DK62592D0 (fr) * 1992-05-14 1992-05-14 Novo Nordisk As
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
JPH07118156A (ja) * 1993-10-26 1995-05-09 Nippon Zoki Pharmaceut Co Ltd アデノシンデアミナーゼ阻害剤
JPH08269083A (ja) * 1995-04-03 1996-10-15 Banyu Pharmaceut Co Ltd Ｎ６−置換アデノシン誘導体
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033591A1 (fr) * 1996-03-13 1997-09-18 Novo Nordisk A/S Procede de traitement d'affections associees aux cytokines chez les mammiferes
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NO20002359L (no) 2000-07-05
EA003087B1 (ru) 2002-12-26
CN1217952C (zh) 2005-09-07
EP1030856A2 (fr) 2000-08-30
DE69825779T2 (de) 2005-08-25
ID24758A (id) 2000-08-03
HUP0004102A3 (en) 2002-09-30
PL340873A1 (en) 2001-03-12
IS5479A (is) 2000-05-03
CA2309202C (fr) 2008-06-17
IL135966A0 (en) 2001-05-20
ATE273989T1 (de) 2004-09-15
NO20002359D0 (no) 2000-05-05
EE200000283A (et) 2001-08-15
YU26800A (sh) 2002-12-10
AP2000001804A0 (en) 2000-06-30
ES2222619T3 (es) 2005-02-01
KR20010031878A (ko) 2001-04-16
US6740644B2 (en) 2004-05-25
TR200001937T2 (tr) 2000-11-21
EP1030856B1 (fr) 2004-08-18
CN1285844A (zh) 2001-02-28
CA2309202A1 (fr) 1999-05-20
NZ504336A (en) 2002-11-26
JP2001522859A (ja) 2001-11-20
HRP20000277A2 (en) 2000-10-31
GB9723590D0 (en) 1998-01-07
HUP0004102A2 (hu) 2001-04-28
AU1666599A (en) 1999-05-31
EE04499B1 (et) 2005-06-15
US6544960B1 (en) 2003-04-08
AU763414B2 (en) 2003-07-24
US20030158146A1 (en) 2003-08-21
DE69825779D1 (de) 2004-09-23
WO1999024451A3 (fr) 1999-08-19
WO1999024451A2 (fr) 1999-05-20
BR9813989A (pt) 2000-09-26
EA200000398A1 (ru) 2000-12-25
IL135966A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
SK6702000A3 (en) Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use
SK6712000A3 (en) Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use
HRP20000275A2 (en) Chemical compounds
EP4332102A1 (fr) Composé d'isoquinolone et son utilisation
US20100062994A1 (en) Adenosine Receptor Antagonists
RU2093513C1 (ru) Производные 9-деазагуанины или их таутомеры и фармацевтическая композиция, обладающая способностью ингибировать активность пуриннуклеозид фосфорилазы у млекопитающих
EP3670500A1 (fr) Composé chimique, composition pharmaceutique de celui-ci, utilisation et application correspondantes
US20040162422A1 (en) Chemical compounds
US5998388A (en) Adenosine derivatives
US6100246A (en) Spiro-piperidine derivatives as inhibitors of nitric oxide synthase
CZ20001665A3 (cs) Deriváty adenosinu
US4992535A (en) Methods of making novel R and S diastereomers of N6 -[(2-hydroxypropyl)aryl]adenosines
CZ20001666A3 (cs) Deriváty adenosinu
CZ20001667A3 (cs) Deriváty adenosinu
MXPA00004431A (en) Adenosine a1 receptor agonists
MXPA00004428A (en) Adensine a1 receptor agonists
MXPA00004429A (en) Adenosine a1 receptor agonists